University of Hertfordshire

Standard

Negative symptoms as key features of depression among cannabis users : A preliminary report. / Bersani, G.; Bersani, F. S.; Caroti, E.; Russo, P.; Albano, G.; Valeriani, G.; Imperatori, C.; Minichino, A.; Manuali, G.; Corazza, O.

In: European Review for Medical and Pharmacological Sciences, Vol. 20, No. 3, 2016, p. 547-552.

Research output: Contribution to journalArticle

Harvard

Bersani, G, Bersani, FS, Caroti, E, Russo, P, Albano, G, Valeriani, G, Imperatori, C, Minichino, A, Manuali, G & Corazza, O 2016, 'Negative symptoms as key features of depression among cannabis users: A preliminary report', European Review for Medical and Pharmacological Sciences, vol. 20, no. 3, pp. 547-552.

APA

Vancouver

Author

Bersani, G. ; Bersani, F. S. ; Caroti, E. ; Russo, P. ; Albano, G. ; Valeriani, G. ; Imperatori, C. ; Minichino, A. ; Manuali, G. ; Corazza, O. / Negative symptoms as key features of depression among cannabis users : A preliminary report. In: European Review for Medical and Pharmacological Sciences. 2016 ; Vol. 20, No. 3. pp. 547-552.

Bibtex

@article{b959c4e9be644004a4d5b62d3c1e437f,
title = "Negative symptoms as key features of depression among cannabis users: A preliminary report",
abstract = "OBJECTIVE: Cannabis use is frequent among depressed patients and may lead to the so-called {"}amotivational syndrome{"}, which combines symptoms of affective flattening and loss of emotional reactivity (i.e. the socalled {"}negative{"} symptomatology). The aim of this study was to investigate the negative symptomatology in depressed patients with concomitant cannabis use disorders (CUDs) in comparison with depressed patients without CUDs. PATIENTS AND METHODS: Fifty-one patients with a diagnosis of Major Depressive Disorder (MDD) and concomitant CUD and fiftyone MDD patients were enrolled in the study. The 21-Item Hamilton Depression Rating Scale (HDRS) and the negative symptoms subscales of the Positive and Negative Syndrome Scale (PANSS) were used to assess depressive and negative symptomatology. RESULTS: Patients with cannabis use disorders presented significantly more severe negative symptoms in comparison with patients without cannabis use (15.18 ± 2.25 vs 13.75 ± 2.44; t100 = 3.25 p = 0.002). DISCUSSION: A deeper knowledge of the {"}negative{"} psychopathological profile of MDD patients who use cannabis may lead to novel etiopathogenetic models of MDD and to more appropriate treatment approaches.",
keywords = "Amotivational syndrome, Cannabis use disorders, Major depressive disorder, Negative symptoms",
author = "G. Bersani and Bersani, {F. S.} and E. Caroti and P. Russo and G. Albano and G. Valeriani and C. Imperatori and A. Minichino and G. Manuali and O. Corazza",
year = "2016",
language = "English",
volume = "20",
pages = "547--552",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Publishers",
number = "3",

}

RIS

TY - JOUR

T1 - Negative symptoms as key features of depression among cannabis users

T2 - A preliminary report

AU - Bersani, G.

AU - Bersani, F. S.

AU - Caroti, E.

AU - Russo, P.

AU - Albano, G.

AU - Valeriani, G.

AU - Imperatori, C.

AU - Minichino, A.

AU - Manuali, G.

AU - Corazza, O.

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: Cannabis use is frequent among depressed patients and may lead to the so-called "amotivational syndrome", which combines symptoms of affective flattening and loss of emotional reactivity (i.e. the socalled "negative" symptomatology). The aim of this study was to investigate the negative symptomatology in depressed patients with concomitant cannabis use disorders (CUDs) in comparison with depressed patients without CUDs. PATIENTS AND METHODS: Fifty-one patients with a diagnosis of Major Depressive Disorder (MDD) and concomitant CUD and fiftyone MDD patients were enrolled in the study. The 21-Item Hamilton Depression Rating Scale (HDRS) and the negative symptoms subscales of the Positive and Negative Syndrome Scale (PANSS) were used to assess depressive and negative symptomatology. RESULTS: Patients with cannabis use disorders presented significantly more severe negative symptoms in comparison with patients without cannabis use (15.18 ± 2.25 vs 13.75 ± 2.44; t100 = 3.25 p = 0.002). DISCUSSION: A deeper knowledge of the "negative" psychopathological profile of MDD patients who use cannabis may lead to novel etiopathogenetic models of MDD and to more appropriate treatment approaches.

AB - OBJECTIVE: Cannabis use is frequent among depressed patients and may lead to the so-called "amotivational syndrome", which combines symptoms of affective flattening and loss of emotional reactivity (i.e. the socalled "negative" symptomatology). The aim of this study was to investigate the negative symptomatology in depressed patients with concomitant cannabis use disorders (CUDs) in comparison with depressed patients without CUDs. PATIENTS AND METHODS: Fifty-one patients with a diagnosis of Major Depressive Disorder (MDD) and concomitant CUD and fiftyone MDD patients were enrolled in the study. The 21-Item Hamilton Depression Rating Scale (HDRS) and the negative symptoms subscales of the Positive and Negative Syndrome Scale (PANSS) were used to assess depressive and negative symptomatology. RESULTS: Patients with cannabis use disorders presented significantly more severe negative symptoms in comparison with patients without cannabis use (15.18 ± 2.25 vs 13.75 ± 2.44; t100 = 3.25 p = 0.002). DISCUSSION: A deeper knowledge of the "negative" psychopathological profile of MDD patients who use cannabis may lead to novel etiopathogenetic models of MDD and to more appropriate treatment approaches.

KW - Amotivational syndrome

KW - Cannabis use disorders

KW - Major depressive disorder

KW - Negative symptoms

UR - http://www.scopus.com/inward/record.url?scp=84992390013&partnerID=8YFLogxK

M3 - Article

C2 - 26914132

AN - SCOPUS:84992390013

VL - 20

SP - 547

EP - 552

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 3

ER -